NINDS Advisory Council Meeting Minutes, May 22-23, 2003

• I. Call to Order and Opening Remarks
• II. Report of the Associate Director for Extramural Research
• III. Report of the Acting Director, NINDS
• IV. Funding Strategy for Fiscal Year 2004
• V. Scientific Presentation - "Local Modulation of Immune System Activity Targeted to Blood Vessels Can Prevent Stroke"
• VI. NINDS/VA Amyotrophic Lateral Sclerosis Collaboration
• VII. Human Genetics Resource Center: DNA and Cell Line Repository
• VIII. Fiscal Year 2004 Proposed Set Aside Initiatives
• IX. Council Subcommittee Reports
• X. Council Review of Pending Applications
• XI. Adjounment

Department of Health and Human Services
Public Health Service
National Institutes of Health
National Advisory Neurological Disorders and Stroke Council

Summary of Meeting¹
May 22-23, 2003

The National Advisory Neurological Disorders and Stroke (NANDS) Council was convened for its 157th meeting on May 22-23, 2003, in the Natcher Conference Center, Room E1/E2, National Institutes of Health, Bethesda, Maryland. Dr. Audrey Penn, Acting Director of the National Institute of Neurological Disorders and Stroke (NINDS), served as Chairperson.

In accordance with Public Law 92-463, the meeting was:

Open: May 22, 2003 --10:40 a.m. to 5:30 p.m.

for the review and discussion of program development, needs, and policy; and

Closed: May 23, 2003 - 8:00 a.m. to 10:15 a.m.

for the consideration of individual grant applications and other business.

Council members present were:

Mr. Ronald Bartek
Mr. Bradley Margus
Dr. Bruce Bean
Mr. Jeffrey Martin
Dr. Keith Black
Ms. Ellyn Phillips
Dr. J. Donald Easton
Dr. Joshua Sanes
Dr. John Griffin
Dr. Sally Shaywitz Dr. Susan Hockfield (5/22 only)
Dr. Ira Shoulson
Dr. Daniel Lowenstein
Dr. Lydia Villa-Komaroff Dr. Peter MacLeish
Mr. Robert Waterman

Council Roster (Attachment 1)

Ex Officio Members present:

Dr. Paul Hoffman, Department of Veterans Affairs
Dr. Geoffrey Ling, Department of Defense

Council Ad Hoc Consultant

Dr. Apostolos Georgopoulos, University of Minnesota

Members of the public present for portions of the open meeting included:

Dr. William Greenough, University of Illinois
Dr. Elizabeth Shuster, Mayo Clinic
Ms. Christina Clark, ALS BioTeam
Mr. Scott Jenkins, The Blue Sheet
Ms. Michelle Rodrigues, SRI
Ms. Jamie Robinson
Mr. Robert Balkam, Restless Leg Syndrome Foundation
Ms. Barbara Goldman, SFN

NINDS employees present for portions of the meeting included:

Dr. Audrey S. Penn Dr. Constance Atwell Dr. Paul Nichols Dr. Robert Baughman Dr. Eugene Oliver Dr. Alan Willard Dr. Arlene Chiu Dr. Toby Behar Dr. Emmeline Edwards Ms. Cikena Reid Ms. Lynn Morin Dr. John Marler Dr. Claudia Moy Dr. Raul Saavedra Ms. Marian Emr Dr. Scott Janis Dr. Naomi Kleitman Ms. Quandra Scudder Dr. Story Landis Dr. Thomas Miller Dr. Ursula Utz Ms. Nena Wells Ms. Susan Free Ms. Marvene Horwitz Ms. Gladys Bohler Dr. Eugene Major Dr. Joanne Odenkirchen Mr. Michael Loewe Dr. Ronnie Horner Ms. Christina King Ms. Margo Warren Dr. Cynthia McCormick Dr. Linda Porter Dr. JoAnn McConnell Mr. Robert Loughlin Dr. Barbara Radziszewska Ms. Janice Cordell Dr. Katherine Woodbury Harris Dr. Melinda Kelley Ms. Brenda Kibler Dr. Jill Heemskerk Dr. Danilo Tagle

Dr. Paul Sheehy Ms. Ruth Linn Mr. Andy Baldus Mr. Paul Girolami Dr. Diane Murphy Dr. Henry Khachaturian Dr. Deborah Hirtz Ms. Sylvia Parsons Dr. Tom Jacobs Dr. Yuan Liu Dr. Meenaxi Hiremath Dr. Ernest Lyons Dr. Bernard Ravina Dr. Katrina Gwinn-Hardy Ms. Liz Geiger Ms. Margaret Jacobs Mr. Levon Parker Dr. Gabriel Leblanc Ms. Maureen Hambrecht Dr. Robert Finkelstein Ms. Stephanie Clipper Dr. Frances Yee Dr. Daofen Chen Dr. Diane Lawrence Dr. Maureen Beanan Dr. Laura Mamounous Ms. Lorraine Fitzsimmons Dr. Peter Gilbert Dr. Merrill Mitler Dr. Richard Crosland Ms. Karen Dunlap Mr. Gahan Breithaupt Ms. Nancy Hart Mr. Phillip Wiethorn Dr. Al Kerza Dr. David Jett Dr. Gaya Jeyarasasingam Dr. Mary Ellen Michel Dr. Heather Rieff Dr. Michael Nunn Ms. Patricia Turner

Other Federal employees present for portions of the meeting included:

Dr. Doug Anderson, Department of Veterans Affairs
Dr. Adam Richman, Department of Veterans Affairs
Dr. William Goldberg, Department of Veterans Affairs
Dr. Betsy Ra, CSR
Dr. William Benzing, CSR
Dr. David Armstrong, CSR
Dr. Sherry Stuesse, CSR
Dr. Rene Etcheberrigaray, CSR
Dr. Michael Martin, CSR
Dr. Michael Lang, CSR

I. Call to Order and Opening Remarks

Dr. Audrey Penn, Acting Director, NINDS, welcomed Council members, guests and staff to the 157th Council meeting. She expressed her regret for the death of Council member Jeanne Carpenter, whose representation of epilepsy patients and contribution to the NANDS Council will be greatly missed. In other Council news, Dr. Apostolos Georgopoulos has left the Council due to government regulations governing foreign activities, but he is attending today as an ad hoc member. It is the last Council meeting for Drs. John Griffin, Peter MacLeish, Joshua Sanes, and Mr. Robert Waterman. However, if the NINDS-nominated Council slate is not approved by the Department of HHS by September, the current members' terms will be extended through the next Council meeting.

Top

II. Report of the Associate Director for Extramural Research

Government in the Sunshine Act and the Federal Advisory Committee Act

Dr. Constance Atwell, Associate Director for Extramural Research, NINDS, reviewed the Government in the Sunshine Act and the Federal Advisory Committee Act, which require the Department of Health and Human Services to open to public observation as many advisory committee meetings as possible, including the National Advisory Councils. The NANDS Council meeting was open to the public, except during the review of grant applications. Notice of the date and place for the Council meeting was published in the Federal Register thirty days prior to the meeting.

Conflict of Interest

The regulations concerning conflict of interest were reviewed. Council members were reminded that materials furnished for review purposes and discussion during the closed portions of the meeting are considered privileged information. All Council members present signed a statement certifying that they did not participate in the discussion of, or vote on, an application from any organization, institution, or any part of a university system, of which they are an employee, consultant, officer, director or trustee, or in which they have a financial interest. Institutions or organizations which have multi-campus institution waivers, or are specifically designated as separate organizations under 18 U.S.C. 208(a), are exempt from this provision. Council members were given the list of grant applications from which the Council members would need to recuse themselves, if discussed. Council members were also reminded that they need to remove themselves from discussions of applications from any institution from which they have received an honorarium for one year from the time the honorarium was received. If the Council member's participation is deemed critical to the discussion; however, a waiver may be granted by the Institute.

Consideration of Minutes of Previous Council Meeting

The minutes of the Council meeting of February 6-7, 2003, were considered and accepted as written.

Consideration of Dates for Future Council Meetings

The following dates for future Council meetings were reconfirmed:

September 18-19, 2003 (Thursday and Friday)

February 12-13, 2004 (Thursday and Friday)

May 27-28, 2004 (Thursday and Friday)

September 9-10, 2004 (Thursday and Friday)

February 10-11, 2005 (Thursday and Friday)

May 26-27, 2005 (Thursday and Friday)

September 15-16, 2005 (Thursday and Friday)

Other Items

Reports Book--The Reports Book consists of applications that have been designated for funding since the last Council meeting. It includes interim actions that have been taken and the status of applications that were identified for High Program Priority.

Expedited Review Process--Of the 176 applications that were eligible for expedited award, 112 applications have already been awarded. Dr. Atwell thanked Grants Management Branch Chief Michael Loewe and his staff for completing the large number of awards.

Staff News--Dr. Atwell announced that Dr. Al Kerza, program director in the Neural Environment Cluster, was retiring after 26 years in government service. She acknowledged his key role in developing the AIDS portfolio and infectious disease area for NINDS. In other news, Dr. Atwell announced that Dr. Penn received the "Distinguished Alumnae of the Year" award from Columbia University and offered her congratulations.

Top

III. Report of the Acting Director, NINDS

Budget--Dr. Penn presented the NIH and NINDS FY02, FY03, and proposed FY04 budgets. She noted that the increases in FY02 and FY03 were 12.9 percent and 11.2 percent, respectively. The President's FY04 proposed budget increase for NINDS was 0.9 percent. However, since it was very early in the budget process, the final FY04 budget was still undetermined. She stated that the Institute would make every effort to either maintain the current payline or one close to it in FY04, but it may not be possible.

Congressional Hearings--The House Committee hearings had taken place. Committee members raised particular questions related to Parkinson's disease, spinal muscular atrophy, muscular dystrophy, and tuberous sclerosis.

NIH Roadmap Report--The NIH Director's Roadmap project is currently in Phase III. The project began in the summer of 2002 with small brainstorming groups. Following the first set of meetings, a larger meeting was organized around the theme of clinical research, which involved several members of the academic community, private industry, and voluntary organizations. The intent was to determine what large projects would be needed, and once those were defined, to develop plans to support them. There are three major themes which served as guides for the Roadmap working groups: 1) New pathways to discovery, 2) Research teams of the future, and 3) Re-engineering the clinical research enterprise. Dr. Penn reviewed the membership and goals of each roadmap working group. The next step would be a meeting in mid-June to discuss the recommendations of the 15 groups working on aspects of these themes that have been meeting over the last several months. NINDS program staff have participated in many of the working groups, with Dr. Penn chairing the regenerative medicine committee's adult stem cell subcommittee.

Spinal Muscular Atrophy Contract-Dr. Penn described the Spinal Muscular Atrophy (SMA) contract as a pilot project with heavy Institute involvement, both in its design and also in the selection of the steering committee. The Request for Information and Request for Proposals for this contract have been issued. Once the contractor is selected, the project will be submitted to Council for its review. The steering committee will be made up of investigators from academia and private industry and will be responsible for selecting the subcontractors to carry out the terms of the contract. The steering committee will also be responsible for periodic review of the contract.

New NINDS Director Search--There was no further news to report on the director search.

Top

IV. Funding Strategy for Fiscal Year 2004

Dr. Atwell announced that the President's budget for FY04 reflects a 0.9 percent increase over FY03, which is significantly less than the increases in the last five years. She opened the FY04 funding strategy discussion with a presentation of the broad budget categories, using the President's FY04 budget figure. NINDS anticipates that 38 percent of the budget will go toward competing grants and 62 percent toward the commitment base. The total budget would be $1,287,561,000. Dr. Atwell reviewed budget categories for FY02, FY03, and FY04, noting that the success rate and payline have remained relatively stable over recent years. If the same funding strategy were used in FY04 as FY03, the resulting payline would be 19 percent. Many institutes have paylines below this amount; a few have higher paylines. Dr. Griffin commended Institute staff for their expert management of the budget, in spite of the fluctuations in the budgets from year to year. Council was told that the Institutes/Centers' (I/Cs) budgets will be affected by the NIH director's roadmap funding decisions; it is possible that the NIH director could shift funds among I/Cs. Dr. Sanes also commended the staff's budget management and expressed his appreciation for the opportunity to have served on an NINDS study section, the Board of Scientific Counselors, and on the Council. He praised the Institute for playing a critical role in moving neuroscience forward, and he recognized several program staff for their dedication and commitment to the Institute's mission. While believing that the private sector offers the best system for taking the successes of basic science to treatment trials, Dr. Sanes said that the Government fills the critical role of funding the basic research that makes treatment advances possible. Funding translational research is important but will not obviate the need for the basic science research needed to address afflictions that will emerge in the future. He believes the U.S. system for funding research is superior because it supports investigator-initiated research.

In terms of the cost of clinical trials, Dr. Lowenstein raised concerns about the process for assigning relative importance to the clinical trial proposals that are presented at the Clinical Trials subcommittee. The proposals are peer reviewed for scientific merit and then ranked by the subcommittee, which may not have the expertise necessary to make that evaluation. He suggested contracting with an expert to perform a meta-analysis of the appropriate scientific field to assess what the potential impact of the trial would be on the nation's health. This would help the subcommittee bring a scientific approach to its ranking decisions. Dr. Shoulson requested that there be a discussion about the Institute's future priorities, and that the Council be provided with data on what has been funded already and what the outcome of those projects have been in terms of the Institute's mission and on public health. The Office of Science Policy and Planning has analyzed the funding initiatives over the last five years and has matched them with the Institute's stated priorities and plans of 1999. They will present their report, which will include any areas that have not yet been addressed, to Dr. Penn. Various scenarios of the budget were discussed, such as adjusting the set-aside budget, changing the automatic reduction percentages for modular and non-modular grants, and changing the amounts set aside for high program priority and clinical trial grants. Instituting a cap on the clinical trials grants was also considered. After extensive discussion, the Council recommended increasing the automatic reduction for modular grants to 7.5 percent and non-modular grants to 12.5 percent and changing the percentage of the set-aside grant initiatives budget to 6 percent. These changes would possibly result in a 21 percent payline. Mr. Margus asked for a presentation at the next Council meeting of an analysis of the Institute's initiatives as they relate to the Institute's objectives.

Top

V. Scientific Presentation: Exercise is Not Just for Fun! Influences on Health and Neural Disorders.

Dr. William Greenough, Professor of Psychology, Psychiatry and Cell and Structural Biology, Beckman Institute, University of Illinois at Urbana-Champaign, reported that the effects of experience upon the synaptic organization of the developing and adult brain are well known in general, although there are differences of opinion regarding some of the details. Less well known are the effects of experience on non-neuronal brain tissues such as vasculature and glia, all of which show dramatic responses to behavioral experience such as exposure to a complex, stimulating environment. To examine the sources of these effects Dr. Greenough's lab has compared effects of exercise, in the presence of very little learning, with the effects of learning, in the presence of very little exercise. They found that some tissue components, such as capillary sprouting, respond primarily to exercise and presumably associated neural activity, while others, such as synapse number, respond primarily to the need to store information. The effects of these structurally-evident changes are manifest in physiological measures of brain function. These findings have also resulted in therapeutic application of experiential therapies to brain damage.

Top

VI. NINDS/VA Amyotrophic Lateral Sclerosis Collaboration

Dr. Paul Sheehy, Program Director, Neurodegeneration Cluster, NINDS, reported that amyotrophic lateral sclerosis (ALS) is a devastating disorder in which those motor neurons that control voluntary movement are selectively and progressively lost. An urgent need for action is based on the fact that there is currently no effective treatment for this, the most common disease of motor neurons. Moreover, recent reports have identified an approximately two-fold increase in the risk of developing ALS among military personnel deployed to southwest Asia during the first Gulf War. Complementary to this need is the opportunity presented by organized and energized research, clinical and patient communities, well-established genes, and metabolic pathways involved in the pathogenesis and animal models available for testing candidate therapies. Despite decades of study, there remain important gaps in our understanding of the continuum of pathogenesis, pathophysiology, treatment, and prevention of ALS. Accordingly, the NINDS, Department of Veteran's Affairs, NIEHS, and the ALS Association are exploring a public/private partnership to solicit applications to support research in three general lines of investigation: causative factors, pathobiology of motor neurons and associated cell types, and the diagnosis and treatment of ALS. A workshop including all potential sponsors and members of the extramural scientific community was held in January 2003, and a draft Request for Applications (RFA) has been developed that is under review by each of the potential sponsors. The RFA proposes using the NIH R21 award mechanism for academic-based applicants and Merit Review Awards for VA-based applicants. Commitments on the order of $2 million (total costs over two years) have been secured from NINDS and the VA; negotiations continue with NIEHS and ALSA.

Top

VII. Human Genetics Resource Center: DNA and Cell Line Repository

Dr. Katrina Gwinn-Hardy, Program Director, Neurogenetics Cluster, NINDS, gave a report on the Human Genetics Resource Center: DNA and Cell Line Repository contract. She reported that the purpose of the Human Genetics Repository is to allow gene discovery in several areas, for example, in complex diseases where a large sample number is needed, among rare diseases, and among ethnic minorities. The Repository will also create standardization within the field of human genetics. The contract for the repository was awarded to the Coriell Institute for Medical Research, which currently serves as a repository for several neurological diseases and has experience with DNA and cell line preparation, patient protection requirements, quality assurance, the administration of fees, and the maintenance of a website and database for their projects. To date, the NINDS Repository has collected 188 samples, with the first samples being available for distribution in October 2003. We have commitments from investigators for the submission of stroke, Parkinson's disease, and epilepsy genes. All NIH grantees are eligible to submit samples to the repository. In order to withdraw cell lines, applicants need to show evidence of an awarded grant and IRB approval for their studies. Program staff are involved in many aspects of the repository, serving in an informational and oversight role. Future goals would be to expand the collections and devise a strategy that would promote greater sharing of genetic material.

Top

VIII. Fiscal Year 2004 Proposed Set Aside Initiatives

Dr. Atwell asked the Council to review for concurrence several initiative concepts submitted by staff for FY 2004. Under the Federal Advisory Committee Act, an outside review group must clear all initiatives that involve funding by the Federal Government. Beginning with the 156^th Council, the Institute asked that Council conduct the outside review for all new initiatives. Concurrence does not imply a mandate to go forward, as the final decision on the initiatives depends on the availability of funds. A motion was made and passed by Council approving the concepts.

Top

IX. Council Subcommittee Reports

Training and Career Development Subcommittee

Dr. Peter MacLeish, Chair of the Training and Career Development Subcommittee, gave an overview of the fellowship program and training grants. There has been a large increase in the number of predoctoral fellowship applications and awards in the last two years. Conversely, there has been a gradual decrease in postdoctoral fellowship applications and awards. Of all the predoctoral grantees, 56 percent are supported on training grants and 44 percent on fellowships. Of all the postdoctoral grantees, 60 percent are supported on institutional grants and 40 percent are supported on fellowships. Due to the recent decrease in number of postdoctoral fellowship applications and awards, this ratio is not likely to change unless a specific policy is implemented to reverse this trend.

The policy of NINDS has been to try to achieve and maintain a ratio of 50:50 for postdoctoral fellows being trained on fellowships (F32) and training grants (T32), respectively. To achieve this ratio, the subcommittee made the following recommendations: (1) Restrict the appointment of postdoctoral trainees on T32 programs to within the first three years of obtaining the doctoral degree, (2) strongly encourage T32 program directors to limit the appointment of postdoctoral fellows on training grants to one year, and no more than two years; and (3) simultaneously encourage or require T32 trainees to apply for their own individual fellowships (F32) or a similarly peer-reviewed fellowship from a private foundation during his/her first or second year of appointment on the training grant for support for additional years of training. There should be two exceptions to the three-year rule for appointment on a T32 grant: (1) when a postdoctoral trainee is changing fields or pursuing new research approaches or methodologies; and (2) the appointment of a clinical fellow to a disease-focused training program. These policies will be articulated in a notice to the research community.

The Subcommittee and staff agreed that it would be useful to research the trainee portfolio to assess which areas the trainees are being trained in. The purpose would be to determine if the targeted fields of research are being reached in order to move the field forward. Staff agreed to conduct this analysis and present the findings at a future Subcommittee meeting. Of particular importance is basic vs. clinical training, specific areas of training, Ph.D. vs. M.D. training, as well as highly-focused vs. broadly-based training. The Council Training Subcommittee will then consider this information and will make additional recommendations regarding the distribution of trainee slots on T32 grants.

Clinical Trials Subcommittee

Dr. Daniel Lowenstein, Chair of the Clinical Trials Subcommittee, reported that the subcommittee discussed two topics: 1) a description by Dr. Scott Janis, Program Analyst from the Clinical Trials group, of the first analysis of the clinical trials application review process, and 2) a presentation of the Clinical Research Collaboration initiative by Dr. John Marler, Associate Director in Clinical Trials. The goal of this initiative is to enlist the participation of community-based neurologists for the recruitment of patients for NINDS-funded clinical trials needing patients. The subcommittee supported the overall, general concept, and believed it will be useful for moving clinical research forward. However, the subcommittee also expressed a wish to be better informed about the planning and implementation of initiatives of this scope, and asked that Dr. Marler make the same presentation to the full Council at a future meeting.

Infrastructure Subcommittee

Dr. Joshua Sanes, Chair of the Infrastructure Subcommittee, reported that the subcommittee discussed three agenda items: 1. Increasing the direct cost of P50 and U54 center grants from $1 million dollars to $1.5 million dollars for projects with a human subjects research component. The recommendation was to increase the cap but to restrict eligibility to centers funded under current announcements that specifically solicit human subjects research, for example, the NINDS Morris K. Udall Parkinson's Disease Research Centers of Excellence, NINDS Specialized Program of Translational Research in Acute Stroke, and NINDS Specialized Neuroscience Research Programs at Minority Institutions. These existing centers through competing supplement applications and new centers would be eligible for the increased cap. 2.) Spinal Muscular Atrophy contract Working Group. The subcommittee was informed that a Working Group is being appointed to establish the framework for the program. The Working Group's recommendations will be discussed at the Infrastructure Subcommittee in September. 3.) NIH Roadmap activities. Dr. Robert Baughman, Associate Director in Technology Development, gave a report on Roadmap infrastructure and translational research activities, which expanded on items that Dr. Penn described in her overview of the Roadmap at the full Council meeting.

Two issues were raised for discussion at the next subcommittee meeting. The first was to consider the purpose and budget impact of using a common payline for multicomponent (e.g. P01 and P50) and single component (e.g., R01 and R21) grants, and as part of this discussion to consider the optimal role of multicomponent program project and center grants. The second was to consider the purposes and implications (e.g., overcoming limitations of staff resources) of the contract/subcontract management strategies that will be used in the SMA contract.

Top

X. Council Review of Pending Applications

This portion of the meeting, involving specific grant review, was closed to the public. The Council gave special attention to applications from foreign institutions and other applications, which needed specific discussion.

Research Training and Career Development Programs

The Council reviewed a total of 95 research career development grant applications; of this total, 73 applications had primary assignment to NINDS, and 53 of them (72.6 percent) were recommended for support in the amount of $7.7 million first-year direct costs. It is anticipated that, of the research career development grant applications competing at this Council, NINDS will be able to pay first-year direct costs of approximately $3.6 million.

Research Grant Awards

The Council reviewed a total of 1,682 research grant applications; of this total, 939 applications had primary assignment to NINDS, and 617 of them (65.7 percent) were recommended for support in the amount of $174.1 million first-year direct costs. It is anticipated that, of the research grants competing at this Council, NINDS will be able to pay first-year direct costs of approximately $67.1 million.

Senator Jacob Javits Neuroscience Investigator Awards

The Senator Jacob Javits Neuroscience Investigator Awards are made to distinguished investigators who have a record of scientific excellence and productivity, who are actively pursuing an area of research of strategic importance, and who can be expected to continue to be highly productive for a seven-year period. Candidates are nominated and selected at each Council meeting. At this meeting, the Council recommended four investigators as Javits awardees.

Small Business Innovation Research and Small Technology Transfer Award Programs

The Council reviewed a total of 195 Small Business Innovation Research (SBIR) and Small Technology Transfer Award (STTR) grant applications; of this total, 109 applications had primary assignment to NINDS and 69 of them (63.3 percent) were recommended for support in the amount of $11.4 million first-year direct costs. It is anticipated that, of the SBIR and STTR applications competing at this Council, NINDS will be able to pay first-year direct costs of approximately $3.3 million.

Top

XI. Adjournment

The meeting was adjourned at 10:15 a.m. on Friday, May 23.

We certify that, to the best of our knowledge, the foregoing minutes and attachments are accurate and complete.

Constance W. Atwell, Ph.D.
Executive Secretary
National Advisory Neurological Disorders
and Stroke Council
Associate Director for Extramural Research
National Institute of Neurological Disorders and Stroke

Audrey S. Penn, M.D.
Acting Chairperson
National Advisory Neurological Disorders
and Stroke Council
Acting Director
National Institute of Neurological Disorders and Stroke

These minutes will be formally considered by the Council at its next meeting. Corrections or notations will be incorporated in the minutes of that meeting.

Top